CM can accordingly be molecularly classified based on the MAPK pathway molecular driver, which includes BRAF mutations, NRAS mutations and NF1 deficiency, accounting for ~80% of tumors [2,4]. Here, BRAF is linked to cutaneous mastocytosis.